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Introduction
Comprehensive preoperative assessment and accurate pre-
diction of surgery- related risks are vital in ensuring better 
patient selection and improved surgical outcomes in the 
management of solid- organ cancers. Postoperative mortal-
ity is one of the most used study endpoints in the 
literature that indicates the quality of cancer surgery and 
postoperative care. Presently, 30- day and in- hospital mor-
tality rates for various cancer types are well documented 
in institutional [1–5] and national statistics [6, 7]. Using 
the Dutch Cancer Registry, Damhuis et al. showed that 
43% of in- hospital deaths for esophageal cancer occurred 
30 days or later after the operation [8]. Extending the 
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Abstract
This study aimed to construct a scoring system developed exclusively from the 
preoperative data that predicts 1- year postoperative mortality in patients with 
solid cancers. A total of 20,632 patients who had a curative resection for solid- 
organ cancers between 2007 and 2012 at Chang Gung Memorial Hospital Linkou 
Medical Center were included in the derivation cohort. Multivariate logistic 
regression analysis was performed to develop a risk model that predicts 1- year 
postoperative mortality. Patients were then stratified into four risk groups (low- , 
intermediate- , high- , and very high- risk) according to the total score (0–43) 
form mortality risk analysis. An independent cohort of 16,656 patients who 
underwent curative cancer surgeries at three other hospitals during the same 
study period (validation cohort) was enrolled to verify the risk model. Age, 
gender, cancer site, history of previous cancer, tumor stage, Charlson comorbid-
ity index, American Society of Anesthesiologist score, admission type, and Eastern 
Cooperative Oncology Group performance status were independently predictive 
of 1- year postoperative mortality. The 1- year postoperative mortality rates were 
0.5%, 3.8%, 14.6%, and 33.8%, respectively, among the four risk groups in the 
derivation cohort (c- statistic, 0.80), compared with 0.9%, 4.2%, 14.6%, and 
32.6%, respectively, in the validation cohort (c- statistic, 0.78). The risk strati-
fication model also demonstrated good discrimination of long- term survival 
outcome of the four- tier risk groups (P < 0.01 for both cohorts). The risk 
stratification model not only predicts 1- year postoperative mortality but also 
differentiates long- term survival outcome between the risk groups.
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mortality period beyond 30 days has the advantage that 
patients who die of surgery- related complications outside 
the hospital are also included in the database. Indeed, 
recent literature suggests that extending postoperative 
mortality beyond 30 days and longer would better indicate 
the true incidence of surgery- related mortality and quality 
of surgical care [9–12]. The ability to predict postopera-
tive mortality risk before surgery provides valuable prog-
nostic information to the clinicians, the patients, and their 
families [13, 14]. The aim of this study was to develop 
and validate a simple risk scoring model using exclusively 
preoperative data that predicts 1- year postoperative mor-
tality for patients with different solid- organ cancers.
Patients and Methods
Patient selection
A retrospective analysis was performed on patients who 
underwent operations for primary solid- organ cancers 
between January 2007 and December 2012 at Chang Gung 
Memorial Hospital (CGMH) Linkou Medical Center (deri-
vation cohort). Patients with either pathologically or 
 radiologically proven malignancies undergoing a curative 
resection for the primary cancer were included in the 
study. Patients who received a palliative procedure (resec-
tions or bypass surgery) were excluded. In addition, patients 
with skin cancers and superficial urinary bladder cancers 
were also precluded. The validation cohort consisted of 
a group of consecutively operated cancer patients with 
the same selection and exclusion criteria who were enrolled 
over the same study period from the three CGMH  affiliated 
hospitals (Keelung branch, regional hospital; Chiayi branch, 
regional hospital; and Kaohsiung branch, medical center). 
The study was approved by the Institutional Review Board 
in all CGMH branches.
Data collection
The prospectively collected administrative and clinical 
data included patient demographics, American Society of 
Anesthesiologist score (ASA score), and Charlson comor-
bidity index (CCI). Patient demographics, including age, 
gender, Eastern Cooperative Oncology Group performance 
status (ECOG scale), history of previous cancer, preexist-
ing comorbidities, cancer by anatomic location, and clinical 
tumor staging, were recorded prospectively by the primary 
care clinicians using an electronic patient record form. 
The electronic patient record form was introduced in2006 
by the institutional cancer center with the intention to 
improve the quality of cancer patient care after the 
 implementation of Cancer Prevention and Treatment 
Act in Taiwan. The clinical data were completed and 
maintained by the individual multidisciplinary cancer care 
teams and the cancer center. Tumor stage was recorded 
as localized, regional, advanced, and unclassified using 
SEER summary stage classification [14]. American Society 
Anesthesiologist scores were evaluated by the anesthesi-
ologists at preanesthetic evaluation, while CCIs were 
calculated from the electronic patient record forms using 
International Classification of Diseases, Ninth Revision 
(ICD- 9). Patient who had a diagnosis of more than one 
cancer or had received more than one operation for the 
primary tumor during the study period was analyzed 
from the date of operation for the first tumor or the 
first surgery.
Follow- up
All patients were followed up until death or 30 June 
2014. Survival time was determined from the time of 
surgery to death or 30 June 2014. The date of death was 
obtained from the National Registry of Death database 
in Taiwan. The incidences and the mortality rates of can-
cers were obtained from the Taiwan Cancer Registry (TCR).
Statistical analysis
Patient demographic data were summarized as numbers 
and percentages for categorical variables, and medians 
and interquartile ranges (IQRs) for continuous variables. 
The following nine variables were assessed in the uni-
variate logistic regression model (with a binary outcome 
of death or survival at 1 year after operation): gender, 
age (decades), cancer type, history of previous cancer, 
tumor stage, ASA score, ECOG scale, admission type 
(elective or nonelective), and CCI. The optimal category 
of variables was selected in order to generate preliminary 
data with better discrimination of mortality rates. Tests 
for interaction among the nine variables were performed 
using interaction terms in a multivariate logistic regres-
sion model. This model was then used to determine 
independent predictors of 1- year postoperative mortality 
and their odds ratios (ORs). The β–coefficients from 
the final model were used to generate point scores for 
the 1- year postoperative mortality risk. Patients were 
then stratified into four risk groups according to the 
total score obtained from the mortality risk analysis 
using a Cox regression model. Receiver operating char-
acteristic (ROC) curves and the area under the curve 
(c- statistic) were used to determine the accuracy of the 
1- year postoperative mortality risk model. A c- statistic 
>0.70 was considered as a reasonable model. The valid-
ity of the resulting mortality risk model was then  assessed 
by the validation cohort. Overall survival among the 
four risk groups was estimated by the Kaplan–Meier 
1689© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.  
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method, and the differences in survival distributions 
were analyzed by the Log- rank test. SPSS 17.0 software 
(SPSS Inc., Chicago, IL) was used for all statistical 
analyses. A P < 0.05 was considered to be statistically 
significant.
Results
Patient characteristics
A total of 20,632 and 16,656 cancer patients who under-
went a curative resection for primary solid- organ cancers 
were included in the derivation and validation cohorts, 
respectively. Demographic characteristics were similar 
 between the derivation and validation cohorts (Table 1). 
All primary cancers were initially grouped into 12 types 
according to the anatomic locations. These were colorectal, 
head and neck, breast, gynecologic, genitourinary, hepato–
biliary–pancreatic (HPB), stomach and small bowel, thy-
roid, thorax, central nervous system (CNS), esophagus, 
and others. The median follow- ups were 39.5 months 
(IQR, 23.3–60.9 months) and 38.1 months (IQR, 22.0–
59.9 months) in the derivation and validation cohorts, 
respectively. The 1- year postoperative mortality rates were 
9.4%, 10.4%, and 9.8% in the derivation, validation, and 
overall cohorts, respectively.
Table 1. Patient’s preoperative demographic data.
Variable Categories
Derivation cohort Validation cohort Overall
N % N % N %
Total 20,632 100 16,656 100 37,288 100
Gender Male 10,613 51.4 9047 54.3 19,660 52.7
Age Median, IQR 57 48–68 59 50–69 58 49–68
Colorectal 4766 23.1 4405 26.4 9171 24.6
Head and neck 3415 16.6 2751 16.5 6166 16.5
Breast 2364 11.5 1579 9.5 3943 10.6
Gynecologic 2198 10.7 1366 8.2 3564 9.6
Genitourinary tract 1922 9.3 1604 9.6 3526 9.5
Hepato–pancreatic 1760 8.5 1859 11.2 3619 9.7
Primary cancer site Stomach, small bowel 1311 6.4 899 5.4 2210 5.9
Thyroid 1069 5.2 770 4.6 1839 4.9
Thorax 774 3.8 768 4.6 1542 4.1
Central nervous system 466 2.3 223 1.3 689 1.8
Esophagus 246 1.2 233 1.4 479 1.3
Others 341 1.7 199 1.2 540 1.4
Previous cancer history Yes 2190 10.6 2109 12.7 4299 11.5
Tumor stage Localized 4193 20.3 2779 16.7 6972 18.7
Regional 6438 31.2 5064 30.4 11,502 30.8
Advanced 6023 29.2 5215 31.3 11,238 30.1
Unclassified 3978 19.3 3598 21.6 7576 20.3
0 8646 41.9 6494 39.0 15,140 40.6
1 8548 41.4 6569 39.4 15,051 40.4
ECOG scale 2 2441 11.8 2576 15.5 4981 13.4
3 908 4.4 913 5.5 1882 5.0
4 89 0.4 104 0.6 234 0.6
Admission type Elective 18,239 88.4 13,915 83.5 32,154 86.2
Nonelective 2393 11.6 2741 16.5 5134 13.8
CCI 0 14,900 72.2 10,849 65.1 25,749 69.1
1 4191 20.3 3795 22.8 7986 21.4
2 1056 5.1 1346 8.1 2402 6.4
3 286 1.4 401 2.4 687 1.8
4 126 0.6 173 1.0 299 0.8
≥5 73 0.4 165 1.0 238 0.6
ASA score 1 1418 6.9 1510 9.1 2929 7.9
2 12,476 60.5 10,144 60.9 22,620 60.7
3 6694 32.4 4907 29.5 11,601 31.1
4 and 5 44 0.2 95 0.6 139 0.4
One- year postoperative mortality 1930 9.4 1728 10.4 3658 9.8
ASA, American Society of Anesthesiologist; CCI, Charlson comorbidity index; IQR, interquartile range; ECOG, Eastern Cooperative Group Oncology.
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Longitudinal postoperative mortality rates 
of the derivation cohort
The 1- , 3- , 6- months, and 1- year postoperative mortality 
rates of the derivation cohort, as stratified by the study 
variables, are shown in Table 2. Of note, the 12 anatomy- 
based cancer types were reclassified into five cancer groups 
according to their potential postoperative mortality risk. 
The 1- year postoperative mortality rates were significantly 
higher in male gender, oldest old (>80 year- old), digestive 
tract cancers, CNS cancers, advanced tumor stage, poor 
ECOG scale, nonelective admission, and poor CCI, in 
comparison with the mean 1- year postoperative mortality 
rate of the whole derivation cohort.
Independent predictive factors of 1- year 
postoperative mortality in the derivation 
cohort
The results of the univariate and multivariate analyses 
are shown in Table 3. Age, gender, cancer group, 
history of previous cancer, tumor stage, CCI, ASA 
score, admission type, and ECOG scale were all inde-
pendent variables influencing 1- year postoperative 
mortality.
Risk model, risk group classification and 
model accuracy in the derivation cohort
The 1- year postoperative mortality risk model and 
the scoring system generated from the β–coefficients 
of the multivariate analysis are summarized in Table 4. 
Patients were stratified into low- , intermediate- , high- , 
and very high- risk groups on the basis of the total- risk 
model score; and the corresponding 1- year postoperative 
mortality rates and the ORs of the four risk groups 
in the derivation cohort were shown (Fig. 1). The 
 c- statistic of the four- tier risk model was up to 0.80 
(95% confidence interval [CI], 0.79–0.81); whereas 
the  c- statistics were decreased to 0.68 and 0.64, 
when  constructed by tumor stage and CCI, respectively 
(Fig. 2A).
Table 2. Longitudinal postoperative mortality of cancer patients after radical resections.
Postoperative mortality rate (%)
Variable Category 1- month 3- months 6- months 1- year
Total 0.7 2.2 4.4 9.4
Gender Female 0.6 1.6 3.2 6.7
Male 0.9 2.7 5.5 11.8
Age, years 0–69 0.5 1.4 3.2 7.4
70–79 1.3 4.0 7.2 14.2
≥80 2.9 7.7 11.8 23.2
Primary tumor site Breast, thyroid 0.2 0.6 1.0 1.7
CRC, GYN, and GU 0.7 1.8 3.4 7.1
HN, Esophagus, thorax, and others 0.5 2.0 4.8 12.7
HPB, stomach, and small bowel 1.7 5.0 9.3 17.2
CNS 1.9 5.2 10.3 22.5
Previous cancer history No 0.7 2.1 4.1 8.9
Yes 0.9 3.1 6.3 13.0
Tumor stage Localized 0.5 1.2 2.0 4.0
Regional 0.8 2.5 5.7 12.8
Advanced 2.5 7.2 14.2 28.8
Unclassified 1.1 3.4 5.0 9.3
ECOG scale 0–1 0.6 1.6 3.4 7.4
2–3 1.5 4.8 8.9 18.5
4 9.0 16.9 25.8 38.2
Admission type Elective 0.5 1.5 3.3 7.4
Nonelective 2.6 7.1 12.7 23.9
CCI 0 0.3 1.2 3.1 7.4
1–2 1.1 3.2 6.2 12.7
3–4 8.0 14.8 18.7 26.9
≥5 24.7 49.3 57.5 60.3
ASA score 1–2 0.3 1.1 2.6 6.1
3–5 1.6 4.3 8.1 16.0
ASA, American Society of Anesthesiologist; CCI, Charlson comorbidity index; ECOG, Eastern Cooperative Oncology Group; HPB, hepato–biliary– 
pancreatic; CNS, central nervous system.
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Validation of risk model accuracy for 1- year 
postoperative mortality
In the validation cohort, the 1- year postoperative mortality 
rates were 0.9%, 4.2%, 14.6%, and 32.6% for the low- , 
intermediate- , high- , and very high- risk groups, respectively, 
which were comparable to those of the derivation cohort 
(Fig. 1). Again, the c- statistics of these four- tier risk model 
was 0.78 (95% [CI], 0.77–0.79); whereas the c- statistics 
were decreased to 0.70 and 0.60, when constructed by 
tumor stage and CCI, respectively (Fig. 2B).
Survival outcomes of the derivation and 
validation cohorts
At the date of study censor, 9.4% of patients in 
the  derivation cohort and 10.4% of patients in 
the  validation cohort died 1 year after surgery. 
Statistically significant survival differences out to 
80 months  postoperatively were observed between 
the four risk model groups in both derivation 
(P < 0.001) and  validation cohorts (P < 0.001) (Fig. 3, 
Table 5).
Table 3. Univariate and multivariate analysis for 1- year postoperative mortality in derivation cohort.
Variable Categories N
No. of 1- year 
postoperative 
mortality (%)
Univariate Multivariate
OR 95% CI P OR 95% CI P
Gender Female 10,019 676 (6.7) 1 1
Male 10,613 1254 (11.8) 1.85 1.68–2.04 <0.001 1.17 1.04–1.31 0.008
Age 0–69 16,138 1192 (7.4) 1 1
70–79 3383 480 (14.2) 2.07 1.85–2.32 <0.001 1.57 1.38–1.80 <0.001
≥80 1111 258 (23.2) 3.79 3.26–4.41 <0.001 2.67 2.23–3.21 <0.001
Primary 
cancer site
Breast or 
thyroid
3433 60 (1.7) 1 1
CRC, GYN, 
and GU
8886 632 (7.1) 4.3 3.29–5.63 <0.001 2.06 1.55–2.74 <0.001
HN, 
Esophagus, 
Lung, and 
others
4776 605 (12.7) 8.15 6.23–10.7 <0.001 6.53 4.88–8.72 <0.001
HPB, stomach, 
and small 
bowel
3071 528 (17.2) 11.7 8.89–15.3 <0.001 5.48 4.08–7.35 <0.001
CNS 466 105 (22.5) 16.4 11.7–22.9 <0.001 14.3 9.94–20.6 <0.001
Previous 
cancer 
history
No 18,442 1645 (8.9) 1 1
Yes 2190 285 (13.0) 1.53 1.34–1.75 <0.001 1.54 1.33–1.790 <0.001
Tumor stage Localized 10,329 418 (4.0) 1
Regional 8194 1049 (12.8) 3.48 3.09–3.92 <0.001 3.74 3.30–4.24 <0.001
Advanced 1366 394 (28.8) 9.61 8.25–11.2 <0.001 13.8 11.6–16.4 <0.001
Unclassified 743 69 (9.3) 2.43 1.86–3.17 <0.001 2.99 2.23–4.00 <0.001
ECOG scale 0–1 17,194 1278 (7.4) 1 1
2–3 3349 618 (18.5) 2.82 2.54–3.13 <0.001 1.47 1.30–1.67 <0.001
4 89 34 (38.2) 7.69 5.00–11.8 <0.001 2.63 1.60–4.31 <0.001
Admission 
type
Elective 18,239 1358 (7.5) 1 1
Nonelective 2393 572 (23.9) 3.91 3.50–4.35 <0.001 2.04 1.79–2.32 <0.001
CCI 0 14,900 1107 (7.4) 1 1
1–2 5247 668 (12.7) 1.82 1.64–2.01 <0.001 1.23 1.10–1.38 <0.001
3–4 412 111 (26.9) 4.60 3.67–5.76 <0.001 2.66 2.04–3.47 <0.001
≥5 73 44 (60.3) 18.9 11.8–30.3 <0.001 9.43 5.45–16.3 <0.001
ASA score 1–2 13,894 850 (6.1) 1 1
3–5 6738 1080 (16.0) 2.93 2.66–3.22 <0.001 1.44 1.29–1.62 <0.001
ASA, American Society of Anesthesiologist; CCI, Charlson comorbidity index; ECOG, Eastern Cooperative Oncology Group; HPB, hepato–biliary– 
pancreatic; CNS, central nervous system.
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Discussion
In the present study, we audited the longitudinal mortal-
ity rates on a large cohort of patients with solid- organ 
cancers who had undergone a curative resection in a 
tertiary referral medical center within a 6- year period. 
Of the solid- organ cancers identified lung, liver, colorectal, 
breast, head and neck, prostate, gastric, pancreatic, 
 esophageal, and gynecological cancers, in the order of 
decreasing prevalence, represent the ten leading causes 
Table 4. Score calculation to predict 1- year postoperative mortality in derivation cohort.
Variable Categories β- coefficient (SE) P- value Point score
Gender Female (reference) 0 0
Male 0.06 (0.02) 0.008 1
Age 0–69 (reference) 0 0
70–79 0.17 (0.03) <0.001 2
≥80 0.37 (0.03) <0.001 4
Primary cancer site Breast, thyroid (reference) 0 0
CRC, GYN, and GU 0.28 (0.05) <0.001 3
HN, Esophagus, Lung, and others 0.71 (0.06) <0.001 7
HPB, stomach, and small bowel 0.62 (0.06) <0.001 6
CNS 1.0 (0.07) <0.001 10
Previous cancer history No (reference) 0 0
Yes 0.17 (0.03) <0.001 2
Tumor stage Localized (reference) 0 0
Regional 0.50 (0.02) <0.001 5
Advanced 0.99 (0.03) <0.001 10
Unclassified 0.41 (0.06) <0.001 4
ASA score 1–2 (reference) 0 0
3–5 0.13 (0.02) <0.001 1
ECOG scale 0–1 (reference) 0 0
2–3 0.13 (0.02) <0.001 1
4 0.36 (0.09) <0.001 4
Admission type Elective (reference) 0 0
Nonelective 0.28 (0.02) <0.001 3
CCI 0 (reference) 0 0
1–2 0.08 (0.02) <0.001 1
3–4 0.37 (0.05) <0.001 4
≥5 0.83 (0.10) <0.001 8
Total score 0–43
ECOG: Eastern Cooperative Oncology Group; SE: standard error.
Figure 1. One- year postoperative mortality rates in cancer patients of derivation and validation cohorts stratified by four- tier risk potential.
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of cancer- related death in Taiwan [15]. Through the in-
tegration of the prospectively collected electronic medical 
records [16], administrative data such as ICD- 9, and 
deceased data from TCR [15], we were able to analyze 
patient demographics, cancer types, history of previous 
cancer, tumor stage, admission type, and associated medi-
cal comorbidities in a nonbiased and quantitative manner 
with minimal missing data. By correlating these preop-
erative data with the 1- year postoperative mortality rates, 
a simple, point scoring, and risk stratification tool was 
developed using multivariate logistic regression method. 
The derivative risk model was then validated by an 
 independent patient cohort and shown to be functioning 
well by the ROC (receiver operation characteristic) curves.
In an era of advancing scientific knowledge and tech-
nology, there is a growing demand from the cancer patients 
and their treating clinicians for a simple risk stratification 
model that could accurately predict postoperative mortality 
and allow for better patient selection to avoid under and 
over treatment, and substantially improve survival out-
comes and life quality [17–20]. The mortality risk model 
was developed entirely from the preoperative data without 
taking into account of specific laboratory results, intra-
operative variables, and immediate postoperative complica-
tions. Factors that are commonly cited in a risk- adjusted 
predictive model for cancer patient outcomes include age, 
gender, cancer site, tumor staging, laboratory data, intra-
operative findings, and postoperative complications. 
However, functional status of a patient, an important 
factor in determining the treatment outcome, is not rou-
tinely collected in the administrative datasets. ECOG scale, 
ASA score, and CCI, either alone or in combination, are 
the three commonly used measurements that reflect the 
functional status of a patient [21–26]. Although other 
investigators have examined the predictive value of these 
functional measurements for postoperative morbidity and 
mortality in the surgical treatment of cancer patients at 
various time points such as 30, 60, or 90 days [19, 25–29], 
the results have been mixed and none has indicated an 
optimal combination. In this study, ECOG scale, ASA 
score, and CCI have all been shown to independently 
influence 1- year postoperative mortality in our cohort of 
cancer patients.
Figure 2. Area under curve for 1- year postoperative mortality in cancer 
patients of derivation (A) and validation (B) cohort constructed by risk 
model, tumor stage, and Charlson comorbidity index, respectively. 
Notably, all P < 0.01 for comparisons among three curves.
Figure 3. Kaplan–Meir survival curves of cancer patients among 
derivation cohort (A) and validation cohort (B) stratified by four- tier risk 
potential.
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In this study, the 12anatomy - based cancer types were 
reallocated into five cancer groups according to their 
 observed 1- year postoperative mortality. As illustrated in 
Table 2, the highest 1- year postoperative mortality rate 
was observed in CNS surgery, followed by HPB and  upper 
gastrointestinal tract, head and neck and lung, colorectal 
and genitourinary, and breast and thyroid surgeries, in 
descending order. This organ- specific postoperative risk 
classification is imperative for two reasons. Firstly, it serves 
to indicate the radicality of the surgical procedures that 
involves removal of vital organs and reduction in their 
functional reserve such as cognition, digestion, and res-
piration. Secondly, it partly reflects the life expectancy 
that is inherently linked to the biology of individual cancer. 
As a result, the probability of 1- year postoperative mor-
tality in colorectal, esophageal, HPB, and brain cancer 
patients were 2.0- , 6.5- , 5.4- , and 14.3- fold, respectively, 
in comparison with that of breast and thyroid cancers 
in this study.
The available evidence would suggest that elderly cancer 
patients tend to have a higher rate of postoperative mor-
bidity, either procedure- related or unrelated, than the 
younger counterparts [17, 19, 20]. In a national population- 
based outcome study, Finlayson et al. reported that  operative 
mortality among the octogenarians was higher than that 
of the younger patients for the three major cancer surger-
ies investigated, namely, esophagectomy, pancreatectomy, 
and lung resection [6]. In addition, long- term survival 
among octogenarians with two or more comorbidities was 
worse than those with fewer comorbid diagnoses. Similarly, 
our recent publication also demonstrated a higher surgical 
morbidity rate in the older group of patients with gastric 
cancer (>80 years) than in the younger group (<80 years, 
18.3% vs. 12.6%, P = 0.035) [16]. Although the 30- day 
mortality rates did not differ significantly between the two 
groups, the in- hospital mortality rate of the older group 
was higher than that of the younger group (6.7% vs. 3.1%, 
P = 0.016). These findings suggested that the elderly pa-
tients were more likely to succumb to postoperative com-
plications because of preexisting or unrecognized 
comorbidities. Robinson et al. have shown that the con-
stellation of frailty, disability, and comorbidity were as-
sociated with 6- month mortality rate up to 15% in elderly 
patients following general, thoracic, vascular, and urologic 
procedures [18]. Based on the risk model developed in 
the present study, a male octogenarian with regional- staged 
gastric cancer would be stratified to the very high- risk 
group, even without any medical comorbidity, and the 
predicted 1- year postoperative mortality rate would be as 
high as 33.8%. This prediction is  astonishingly higher than 
our previously reported 30- day and in- hospital mortality 
rates of 3.0% and 6.7%, respectively [16]. The discrepancy 
in the mortality rates highlights the importance of ap-
propriate patient selection, preoperative risk stratification, 
and refinement of postoperative care.
Undoubtedly, some might argue that 1- year postopera-
tive mortality links with tumor factors and patients’ fac-
tors; thus it should distinguish 1- year relapse- free mortality 
from cancer- specific mortality. According to our data, 
tumor staging accounted for the most influencing com-
ponent among our nine independent variables, up to 
10- point score for advanced stage in our scoring system. 
Advanced tumor stage always indicate more aggressive 
surgical extent and more devastating loss of functional 
reservoir, as well higher probability of early cancer recur-
rence. Taken together, our 1- year postoperative mortality 
would be relevant to either sequel of surgical complica-
tions or early cancer recurrence or both. In many cir-
cumstances, the cause of death was not easily elucidated. 
Nevertheless, from practical point of view, overall post-
operative mortality at 1 year represents our major concern 
rather than relapse- free mortality. Regarding to this per-
spective, our integrated risk model provided a much better 
power (c- statistic, 0.80) to predict 1- year postoperative 
mortality, compared with that by either tumor factor 
(tumor stage, c- statistic, 0.68) or patients’ factor (CCI, 
c- statistic, 0.59) alone.
Lastly but not least importantly, our risk stratification 
model additionally conferred good discrimination and 
 accuracy of long- term survival of four- tier risk groups 
irrespective of their original cancer types and staging, even 
though our initial proof- of- concept was not designed for 
this purpose. Similar to that of 1- year postoperative mor-
tality, long- term survivals of cancer patients after definite 
treatment are in large extent determined by the cancer 
types, tumor stage, and patients’ factors such as age, 
Table 5. Risk group by score calculation in derivation cohort.
Risk group Sum score No. of patient
No. of 1- year 
postoperative 
mortality (%) Odds ratio 95% CI P- value
Low risk 0–5 5441 25 (0.5) 1
Intermediate risk 6–10 7071 270 (3.8) 8.60 5.70–12.9 <0.001
High risk 11–15 5788 846 (14.6) 37.1 24.9–55.3 <0.001
Very high risk ≥16 2332 789 (33.8) 110.8 74.1–156.6 <0.001
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 nutrition, comorbidity, and frailty, which have been 
 incorporated into our risk stratification model. 
Notwithstanding, the high- or very high- risk group cancer 
patients usually underwent less intensively radical surgery 
than those of standard patients, and less frequently receive 
adjuvant chemotherapy, as well more often discontinued 
treatment before completion [30]. Therefore, our risk 
model provided a quick glimpse to crude long- term sur-
vival weighing to 1- year postoperative mortality.
In conclusion, based on two independent population- 
based cohorts, this study has demonstrated a considerable 
gap between the traditionally defined 30- day surgical 
mortality and the 1- year mortality of patients with solid- 
organ cancers undergoing curative resection. It highlights 
a need for a more deliberate and logical preoperative risk 
assessment in order to address the tendency to underes-
timate mortality risk and overanticipate survival gain. Our 
risk stratification model, developed exclusively from the 
preoperative data, not only predicts 1- year postoperative 
mortality but also indicates potential survival outcomes 
in patients with solid- organ cancers.
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